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Pulmonary Toxicity of Bleomycin
by Ian Y. R. Adamson*
Diffuse pulmonary fibrosis is associated with bleomycin administration to humans. The se-
quential reactions oflung cells to this drughave nowbeen investigated in mice followinginjection
of 20 mg/kg bleomycin twice per week for 4 to 8 weeks. Cytoplasmic and subendothelial edema
was first observed in large vessels and by 4 weeks involved the capillaries. The reaction in many
animals did not progress further than endothelial lesions with accumulation ofinterstitial edema.
However 30% ofmice subsequently showed necrosis oftype 1 epithelium with afibrinous exudate
in thealveoli. Fibroblastic organization ofthe fibrinresulted in the deposition ofintraalveolar col-
lagen as well as extensive septal fibrosis by 8 weeks. Epithelial repair, normally accomplished by
type 2 cell proliferation and transformation to type 1 cells, is characterized in this case by division
and metaplasia oftype 2 cells. The metaplastic cells were,however, capable of DNA synthesis and
probably of further cell division. The results indicate that the pulmonary endothelium is the in-
itial site of injury. Extensive damage to these cells could allow the drug access to interstitial and
epithelial cells. Focal necrosis of type 1 epithelium is the critical event that triggers the exudation
offibrin and the subsequent reparative processes.
The antibiotic bleomycin has been used over
the last few years with some success in the treat-
ment of certain types of tumor. The drug was
first isolated from Streptomyces verticillatus by
a Japanese group headed by Umezawa (1,2), who
showed bleomycin to be a mixture of water-
soluble peptides with differences in their ter-
minal amine groups. Separation of these com-
pounds was achieved and clinical trials were car-
ried out on several of them. Initially, the drug
was found to be effective on squamous cell car-
cinoma without inducing the renal toxicity that
was found with related antibiotics, and in recent
years bleomycin has been particularly successful
in the treatment of skin tumors. Advantages of
this therapeutic agent are the apparent absence
of hematopoietic toxicity or immunosuppressive
activity (2). With increasing use, however, it is
now recognized that diffuse pulmonary fibrosis is
a potential complication ofbleomycin therapy.
There have been a few published case reports
indicating pulmonary side effects of the drug, for
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instance, the paper by Rudders and Hensley on a
patient receiving bleomycin for a sarcoma (3).
There was tumor regression, but the patient died
of diffuse interstitial pneumonitis and pulmonary
fibrosis. There have been two cases in Winnipeg
in the last 6 months where similar pulmonary dis-
ease developed during bleomycin therapy for a
tumor. Light and electron microscopy revealed
diffuse pulmonary fibrosis with collagen deposi-
tion in interstitial regions as well as in the air-
ways. Many alveoli were lined by cuboidal epithe-
lial cells, often undifferentiated resembling those
offetal lung.
The problem associated with drug evaluation
from such clinical material is the well known one
of trying to decipher the specific reaction of
bleomycin when several other drugs and, often
radiation, have also been administered to a sick
patient. A pulmonary reaction to the drug might
have been foreseen from the original drug reten-
tion data of Umezawa (1). After one dose of bleo-
mycin to mice, a high level ofdrug was present in
the kidney and lung 5 hr later; by 5 days signifi-
cant amounts were still present in skin and lung,
while other organs were virtually drug-free.
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FIGURE 1. Electron micrograph ofthe wall ofa pulmonary vein after 2weeks bleomycin (20 mg/kgtwice per week). The endothelial
cell is edematous and is separated from basement membrane (BM) at several places by subendothelial blebs (B). L denotes
lumen; SM, smooth muscle; INT, interstitium. x14,000.
Toxicity
There are few experimental studies available
to assess the pulmonary toxicity of bleomycin. In
experiments in which 10 dogs received various
doses of bleomycin intravenously, Fleishman and
co-workers (4) found varying degrees of epithe-
lial reactivity with inflammatory cell infiltrates
and fibrosis as post-injection time increased.
In the present study, a large number of mice
was used in what was initially a pilot experiment
to determine whether bleomycin injection is a
useful model for inducing epithelial metaplasia
and pulmonary fibrosis. From dose/mortality
figures, it became apparent that a higher dose is
needed toproduce pulmonary lesions in mice than
in dogs; a 0.4 mg/kg dose produced lesions in
dogs (4), whereas mice required at least 8-10
times this dose for significant changes to occur. A
detailed chart relating dose to mortality and to
the incidence of pulmonary fibrosis has already
been published (5). The most satisfactory
schedule for producing pulmonary lesions was 20
mg/kg bleomycin IP twice per week for 4 to 8
weeks and sacrifice up to 20 weeks from the first
injection. Most animals developed perivascular
edema with cellular infiltrates, and, in addition, a
proportion of these mice also showed epithelial
metaplasia and fibrosis. The latter changes took
longer to develop and it is likely that some mice,
particularly in high dose groups, died of toxic ef-
fects ofbleomycin on other systems before exten-
sive pulmonary fibrosis occurred.
Pathogenesis
The pathogenesis of bleomycin-induced pulmo-
nary fibrosis was investigated in some detail,
with particular emphasis on the sequential cellu-
lar responses. There are many cell types in the
lung and their reactions to injury are known to be
variable. Most biochemical-toxicologic evalua-
Environmental Health Perspectives 120FIGURE 2. Electron micrograph of capillary and.alveolar epithelium after 4 weeks bleomycin. There is focal necrosis of the type 1
cell (EP1), whereas the type 2 cell (EP2) appears normal; the interstitial space (INT) is edematous. L denotes capillary lumen.
x18,000.
tions treat the lung as a whole, and specific cell
types responding to the injurious agent and the
cellular processes of repair, including cytody-
namic studies of cell turnover, are not made. It
was hoped that a study of these cellular events
would lead to a better understanding of the sites
and mechanisms of injury and perhaps suggest
specific methods ofblocking the reaction.
Morphologic data were obtained by electron
microscopy and by light microscopy on 1 Mm
methacrylate sections. This is a particularly
useful method, since entire lobes of mouse lung
can be embedded per block, and the sections ob-
tained are thin enough to allow cellular identifica-
tion to be made. The reaction now to be described
was qualitatively similar for all doses used; the
timing and extent ofinjury did vary.
Endothelial Reaction
The earliest changes observed by electron mi-
croscopy involved the endothelium of pulmonary
arteries and veins where subendothelial blebs
bulged into vascular lumen resulting in severe at-
tenuation of the endothelial sytoplasm; in addi-
tion, there was intracytoplasmic edema of the en-
dothelial cells (Fig. 1). This was seen as soon as 2
weeks after the start of a 20 mg/kg dose sched-
ule; by 4 weeks these changes were obvious by
light microscopy. Frequently, the perivascular
connective tissue was edematous and contained a
cellular infiltrate, mainly lymphocytes and plas-
ma cells. Lesions oflarge pulmonary vessels were
well developed before changes were seen in the
endothelium of capillaries. These cells also
became swollen and separated from the underly-
ing basement membrane. Diffuse interstitial
edema was observed and the air sacs contained
numerous vacuolated macrophages at this time.
The endothelial cells were therefore identified
as the primary sites of injury and the anatomic
pattern of lesions is likely related to the mode of
drug administration. The preferential suscepti-
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FIGURE 3. Electron micrograph of alveolar epithelium after 4 weeks bleomycin. The alveolar wall is lined by type 2 cells and some
lamellar bodies can be seen in the air sac. The interstitial region is thickened by collagen deposition. x9OOO.
bility ofendothelial cells of arteries and veins can
be related to the fact that the drug is blood borne.
This is in contrast to injury induced by 02 where
the cells on the route of maximum gaseous trans-
fer, the capillary endothelium, are preferentially
injured (6,7).
Epithelial Reaction
In some animals injury did not progress beyond
endothelial swelling with accumulation of inter-
stitial edema; in many, however, there were sub-
sequent changes in the alveolar epithelium. As
noted in other models of lung injury, there is a
differential response of alveolar epithelial cells,
whereby focal necrosis of the squamous type 1
cells was observed and the cuboidal type 2 cells
appeared normal (Fig. 2). By destroying this epi-
thelial barrier, the contents of the interstitium
and ofthe blood may leak through damaged endo-
thelium directly to the alveoli, and in fact, necro-
sis of type 1 cells was frequently associated with
intra-alveolar aggregates of fibrin. Subsequently,
evidence of reparative activity was found in the
alveolar epithelium. Mitotic figures were seen in
some cuboidal cells, and focal areas of alveolar
walls were lined exclusively by this type of epi-
thelium (Fig. 3).
The repair of injured type 1 cells by division of
type 2 epithelium with subsequent transforma-
tion to the squamous form is now established as
a common reparative mechanism for the injured
epithelium by the studies of different models of
lung injury and repair, e.g. 0, and NO2 (8,9). In
the bleomycin-treated mice, there was typthe-
lium and are also similar to the epithelial
forms seen in the bleomycin-injured human lung.
type 1 form, but others seemed to undergo
change to a metaplastic form of epithelium in
which the alveolar lining cells were cuboidal,
possessed microvilli but not lamellar bodies (Fig.
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122FIGURE 4. Electron micrograph ofalveolar epithelium after 5 weeks bleomycin. Epithelial cells form a small tubular structure; cells
have microvilli but no lamellar bodies x4000.
4). Many alveoli were lined by these tubular
forms that resemble undifferentiated fetal epi-
thelium and are also similar to the epithelial
forms seen in the bleomycin-injured human lung.
In some instances, alveoli were lined by flattened
cells, some ofwhich had cilia and resembled bron-
chiolar epithelium (Fig. 5). It may be argued that
bronchiolar epithelial cells had "grown down" in-
to the alveoli to repair the injury but the finding
ofthese metaplastic forms in distal regions of the
lung makes it likely that they were derived from
alveolar epithelial cells, and, in fact, several in-
termediate cell forms were observed. This meta-
plastic pattern of epithelial response to injury
may be related to the agent and severity ofthe in-
jury, or to the fact that there is continuing insult
from the drug in this case rather than the simpler
"one-shot" gas exposure of 02 experiments,
where a return to normal type 1 and 2 cell distri-
bution was found (8).
Fibrosis
As stated above, at areas of type 1 cell necro-
sis, fibrin leaked through the injured epithelium
into the alveoli. Subsequently there was invasion
of this fibrin by fibroblasts which secreted col-
lagen to produce intra-alveolar fibrosis; fibro-
blastic activity was also prominent within the
pulmonary interstitium. The septal and intra-
alveolar fibrosis became progressively more ex-
tensive and severe with time (Fig. 6). In animals
that received a 20 mg/kg dose twice per week for
8 weeks, fibrosis was first observed 4 weeks later
and progressed, becoming diffuse by 4-12 weeks,
by which time the reactive hyperplasia and meta-
plasia ofalveolar epithelium had also occurred.
In mice with the most severe pulmonary dam-
age, fibrosis was observed in the alveolar spaces,
in the alveolar septa and in peribronchial and
perivascular regions. In animals where fibrosis
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[GURE 5. Many alveoli (A) are lined by
weeksbleomcyin. x1O00.
ttened cells, some ofwhich are ciliated. 1 yn methacrylate section, H & E stain, after 5
was not so well developed, fibroblastic activity
could bedemonstrated inthe walls oflarger blood
vessels, whereas there was little change in the
alveolar walls. This brings the morphologic story
full circle, since fibrosis was preferentially pro-
duced adjacent to the initial site of cell injury-
the endothelium oflargervessels.
Cytodynamic Study
Having used these morphologic techniques to
study the pathogenesis of the pulmonary fibrosis
and thus to identify the sites of cellular injury in
the lung, a cytodynariiic investigation was then
undertaken to determine patterns of cellular re-
newal. Some preliminary data is now available,
based on a group of mice injected with 20 mg/kg
bleomycin, twice a week for 4 weeks. At weekly
intervals during and after the treatment, three
mice were injected with 2 ACi/g body weight
of tritiated thymidine and sacrificed 2 hr later.
The lungs were fixed by inflation with glutaral-
dehyde, embedded in methacrylate, and 1 In sec-
tions prepared for autoradiography. These sec-
tions are large enough to allow labeled cell counts
on a large number of cells and thin enough to al-
low precise cellular identification, in contrast to
the thicker paraffin sections where this is seldom
possible. By counting labeled alveolar cells per
1000 nuclei, it was found that there was a sharp
increase in thymidine uptake by lung cells 4-8
weeks after the start ofbleomycin injections.
From autoradiographs, a differential count of
labeled cells was made and compared to controls
at various stages of the reaction. The predomi-
nant labeled cells at the peak of DNA synthesis
were found to be endothelial and epithelial. The
increased number of cells in DNA synthesis and
their anatomic location is a good indication of the
site of antecedent injury where a reparative
mechanism is underway. In this case, labeled en-
dothelial cells were predominantly found in
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FIGURE 6. After 8 weeks bleomycin, showing diffuse septal and intraalveolar fibrosis 1 Sm methacrylate section (silver
methenamine stain). x130.
larger vessels. Injection ofcolchicine may be used
to arrest cells in metaphase and confirm that they
are in mitosis at this time. Examining the epithe-
lial cell population, many of the metaplastic cell
types were labeled, indicating that these cells are
synthesizing DNA. It is likely, therefore, that
they do not all arise by a transformation mecha-
nism, but that some, at least, are capable of divi-
sion.
Mechanism
The mechanism of bleomycin toxicity in the
lung is not fully understood. Various in vitro
studies have indicated effects of bleomycin on a
variety of cell functions, mostly associated with
the nucleus such as chromosomal aberration (10)
or inhibition of cell division (11). By 2 hr after ad-
ministration of '4C-labeled bleomycin, isotope
was found at the cell membrane; by 4 hr, it
reached the nuclear membrane. Necrotic cells
had heavy cytoplasmic label (12). This is sup-
portive evidence for the current theory that cells
contain varying amounts of an inactivation en-
zyme in the cytoplasm, and the cells with low
amounts of this enzyme are most susceptible to
injury by bleomycin. It has been shown in mice
that squamous cell carcinomas readily controlled
by bleomycin possess less inactivating enzyme
than more resistant sarcomas (13).
In a study by Ohnuma (14), homogenates of
various tissues were incubated with bleomycin,
and drug inactivation was followed. Liver, in-
testine, spleen, plasma, kidney all contained more
inactivation enzyme than skin and lung. This is
the inverse of drug retention from in vivo studies
of Umezawa (1), where bleomycin content was
highest in lung and skin, the organs of lowest in-
activation enzyme content.
It is possible, therefore, that the particular
sensitivity of the pulomary endothelium to bleo-
mycin is related to a low level of this inactivating
enzyme in these cells. The vast network of endo-
August 125thelium in the lung is the cell type in first contact
with any blood borne toxin. The endothelium has
been traditionally regarded as a water proof,
coagulation proof lining layer with transport ac-
tivity. Recently this view has been modified by
metabolic studies showing that endothelial cells
bear surface enzymes and receptor sites, e.g.,
certain substances such as gastrin produced in
the gut, appear to be inactivated in the lung (15).
The questions then arise with a compound such as
bleomycin: (a) does the lung have specific binding
sites that remove the agent from the blood and so
is selectively injured, or (b) as suggested above,
is the compound generally toxic but other tissues
have greater amounts of inactivating enzymes
than the lung, which is then selectively damaged?
Injury to the endothelium usually results in the
leakage of fluid and cells into the interstitial
space. In many cases this is reversible with re-
generation of endothelial cells and many of the
bleomycin-injured lungs do not progress beyond
endothelial damage with interstitial edema. The
more critical epithelial injury may be related to
the increasing levels of bleomycin crossing the
damaged endothelium and reaching type 1 cells.
Focal necrosis of this cell allows fibrin and blood
constituents to reach the alveoli. If this is wide-
spread, the animal would die. In this case it is
multifocal and reparative processes are able to
function. Epithelial repair is accomplished by
hyperplasia and metaplasia oftype 2cells with ac-
companying alveolar and septal fibrosis. This is a
fairly common response of the lung to continuing
injury; similar responses have been observed
clinically in diffuse pulmonary fibrosis or fibros-
ing alveolitis. It is possible, therefore, that the
common initiating factor in these disease proc-
esses is the binding to, and subsequent injury of
the endothelium, by agents it cannot metabolize.
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